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Abstract
Objectives: A growing body of evidence shows that
frailty and functional performance predict liver
transplant outcomes. The Organ Procurement and
Transplant Network uses the Karnofsky Performance
Status scale to adjust for transplant center case mix in
assessing quality measures. This study explores the
strength of the relationship between Karnofsky
Performance Status scores and objective measures of
frailty.
Materials and Methods: This observational study
includes 136 adult, first-time liver transplant recipients
at UMass Memorial (2006-2015) who had 2 abdominal
computed tomography scans available (at ≤ 90 
days pretransplant and ≥ 7 days before that). We
analyzed the relationship between Karnofsky
Performance Status and muscle wasting using
absolute and change in psoas muscle size and quality
pretransplant.
Results: The mean age was 55 years, mean Model for
End-Stage Liver Disease was 22, and 34% of patients
were women. In the study group, 50% of patients had
sarcopenia pretransplant and 71.3% demonstrated
declined lean psoas area at an average rate of 11% per
month. Patients who experienced muscle wasting at a
rate of ≥ 1% per month had 2.83 times the risk (95%
confidence interval, 1.18-6.80) of being severely
impaired/disabled pretransplant. The risk increased by
2.32-fold (95% confidence interval, 1.44-3.75) for every
standard deviation decrease in pretransplant lean
psoas area.
Conclusions: Provider-assessed physical health status
moderately correlates with objective measures of
frailty.
Key words: Biostatistics, Frailty, Hepatology, Karnofsky
Performance Status, United Network for Organ Sharing
Introduction
Over the past decade, the growing shortage in organ
availability in the United States has transformed
practice patterns in liver transplantation.1,2 To
minimize mortality on wait lists, the current system
of liver allocation was designed to prioritize the
“sickest first.” Patients are ranked according to the
Model for End-Stage Liver Disease (MELD) score,
which is calculated using 3 objective laboratory values
(creatinine, bilirubin, and international normalized
ratio). Although MELD is a reliable predictor of 
3-month wait list mortality at the population level, it
is a poor predictor of posttransplant mortality.3-5
Recent studies have shown that MELD score
underestimates the risk of wait list and postoperative
mortality among liver transplant patients who are
considered to be “frail.”5-7 It is hypothesized that
frailty may make patients more vulnerable to
stressors such as surgery due to limited physiologic
reserve, leading to worse outcomes when faced with
a stressor such as major abdominal surgery.6,8
Frailty syndrome describes a dynamic and
potentially modifiable phenomenon of decreasing
strength, function, and overall health status as a result
of advanced age, chronic disease and malnutrition,
comorbidities, and other systemic dysfunctions.9,10
Muscle wasting, or sarcopenia, is a hallmark of end-
stage liver disease and has been used as an objective
measure of frailty and predictor of morbidity and
mortality in this population.11-19 However, assessment
of sarcopenia or other proposed objective measures
of frailty have limited clinical utility because they are
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often not practical to assess in the perioperative
setting. Moreover, this measure may be too narrow
to describe global physical health status11 compared
with a phenotypic, clinician-assigned score on a
validated scale of frailty.17
Decreased muscle mass due to reductions in
muscle fiber number and size and strength leads to
declined functional performance.20-22 Functional
status has also been shown to independently predict
liver transplant outcomes.8,23-27 In accordance with a
United Network for Organ Sharing (UNOS)/Organ
Procurement and Transplant Network (OPTN)
mandate, functional status data have been collected
from all US transplant centers using the Karnofsky
Performance Status (KPS) scale for more than a
decade. These data are then used to risk-adjust for
center case mix in the creation of program-specific
reports on outcomes. Although KPS is a widely
validated tool for assessment of global physical
function across many disease indications and has been
used clinically and in clinical trials for over 60
years,25,28-33 its validity in a liver transplant population
remains unknown. Although analytic morphomic
research has been used to identify a strong correlation
between objective measures of sarcopenia and global
assessments of physical health status, the study was
conducted in a population of older (> 70 years)
general surgery patients and not in liver transplant
patients.34 There remains a gap in the literature on
defining and understanding the mechanisms
underlying the frailty phenotype for liver transplant
patients. This will be the first study to describe the
relationship between phenotypic and physiologic
signs and symptoms of frailty syndrome in a liver
transplant population.
In this study, our aim was to describe the
relationship between provider-assessed functional
status (KPS) and objective measures of sarcopenia,
collected using validated analytic morphomic
methodology.
Materials and Methods
Study design and population
This retrospective cohort study included adults who
underwent first-time liver transplant at UMass
Memorial Healthcare Center (UMMHC) between
January 1, 2006, and October 31, 2015, a 781-bed,
tertiary care medical center located in Worcester,
Massachusetts, USA. The UMMHC transplant
program includes adult and pediatric liver, kidney,
and pancreas transplants. In 2012, this center
performed more liver transplants than any other
program in the New England area of the United
States.35 Patients without both a “pretransplant” (≤ 90
days before transplant) abdominal computed
tomography (CT) scan (n = 228) and a referent
(“baseline”) CT scan at least 7 days before the
pretransplant CT (n = 28) or patients who were missing
data on functional status at transplant (n = 3) were
excluded (Figure 1). This study was approved by the
UMass Medical School Institutional Review Board.
Data collection and variable definitions
Muscle measures
Muscle measurements were collected from CT scans
performed as part of routine clinical care. Patients
who are on the UMMHC liver transplant wait list
undergo routine abdominal imaging at the time of
candidacy evaluation and every 6 to 12 months until
transplant, depending on their primary diagnosis.
Baseline and pretransplant psoas muscle size (cross-
sectional area, in mm2) and quality (density,
Hounsfield units [HU]), which included both left and
right psoas muscles, were measured at the L4
vertebral level superior plate according to analytic
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Figure 1. Study Inclusion/Exclusion Flow Chart
morphomic methodology.12 All measures were
collected by a UMass radiology attending physician
with fellowship training in abdominal radiology (AS)
using tools built into the radiology management
system (General Electric Centricity Radiology
Information System/Picture Archiving and
Communication System).
Intrarater reliability was confirmed using test-
retest methodology prior to initiation of study data
collection.36 Briefly, this approach involves re-
ascertainment of the same patients, using the same
tools and administered by the same research staff,
ideally 2 weeks apart to prevent recall bias. We used
images from patients who did not otherwise meet
study inclusion criteria. We used power calculations
to determine that a sample that was 5% of the target
study sample (n = 125), which included 4 images per
patient, would be sufficient to determine good
reliability, defined as ≥ 90% correlation using Pearson
correlation coefficient. Correlation between the
identical images measured 2 weeks apart was found
to be 97%.
Individual psoas muscle measurements were
combined to create the following variables: total
psoas area (TPA; left + right cross-sectional area, mm2),
mean density ([left + right density]/2, HU), lean psoas
area (LPA; TPA × [mean density+85]/170, mm2), 
and stature-normalized.15 We determined LPA
(LPA/height2, mm2/m2) for each time point. These
measures were explored as follows: (1) sarcopenia
pretransplant (pretransplant LPA relative to “normal”),
(2) relative sarcopenia or extent of muscle wasting
(relative LPA change from baseline), and (3) muscle
wasting rate (rate of relative change per month).
Normal sarcopenia pretransplant was defined using
sex-specific LPA averages reported in a sample of
over 1200 elective surgery patients37 and assessed at
a single time point (pretransplant) of sarcopenia
(sarcopenic/not sarcopenic: > 1 standard deviation
[SD] below average/≤ 1 SD above average, with
cutoff points of 1488.4 mm2 for men and 
974.8 mm2 for women). Cutoff points were used to
facilitate comparability with other studies. Relative
sarcopenia uses a patient’s own “baseline” (psoas
measures from earliest available abdominal CT scan)
as the referent, measured as patient score pre -
transplant minus baseline LPA/baseline LPA (%).
Because this was a retrospective study, time between
scans was not uniform among patients. We therefore
standardized relative change in LPA per the number
of months between CT scans (%/month). Relative
change variables were explored as both continuous
variables and grouped into tertiles.
Functional status
Functional status was defined using the KPS scale,
which is described in Table 1. The KPS scale was
designed to be assessed by providers and has been
widely used and validated in many different
populations, including patients with end-stage renal
disease.25,28,29,31-33,38-42 The original KPS is an 11-tiered
scale, which decreases from a maximum of “100%:
normal, no complaints, no evidence of disease” to
“0%: dead” in 10% increments. A collapsed, 3-tiered
version is also available and has high interrater
reliability.25,38,43 We assigned labels to summarize
extent of functional impairment/disability in 
each respective category as follows: none/normal
function (category A: 80%-100%), moderate
limitations (category B: 50%-70%), and severely
impaired disabled (category C: ≤ 40%). We explored
KPS as a continuous, categorical, and binary variable.
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table 1. Karnofsky Performance Status Scale and Variable Handling
Condition % Rating Criteria
A (“none/normal”) 100 - Normal, no complaints; no evidence of disease
• Able to carry on normal activity and to work; no special care needed 90 - Able to carry on normal activity; minor signs or symptoms of disease
80 - Normal activity with effort; some signs or symptoms of disease
B (“moderate”) 70 - Cares for self; unable to carry on normal activity or to do active work
• Unable to work; able to live at home and care for most personal 60 - Requires occasional assistance but is able to care for most of his 
needs; varying amount of assistance needed personal needs
50 - Requires considerable assistance and frequent medical care
C (“severe”) 40 - Disabled; requires special care and assistance.
• Unable to care for self; requires equivalent of institutional or 30 - Severely disabled; hospital admission is indicated although death not 
hospital care; disease may be progressing rapidly imminent
20 - Very sick; hospital admission necessary; active supportive treatment 
necessary
10 - Moribund; fatal processes progressing rapidly
0 - Dead
Abbreviations: Author-assigned variable labels are shown in parentheses.
covariates of interest
Potential confounders of interest were selected based
on literature review and a priori knowledge.
Characteristics of interest included sociodemographics,
body habitus, comorbidities, liver diagnoses, and
illness severity (laboratory-based MELD scores, Child-
Pugh scores, sequelae of liver disease, and medical
condition). Because previous studies have shown
substantial differences in degree and mechanism of
muscle wasting in men versus women, patient sex
was a key characteristic that we explored in the most
depth.
These data were collected from the UMMHC
transplant registry, which included variables
collected and submitted by mandate to UNOS/SRTR
database and other clinical and laboratory variables
from patients’ electronic medical records that are
automatically imported into the registry in real time.
Statistical analyses
Univariate and bivariate distributions of muscle
measures, functional status, and key characteristics
at baseline and pretransplant were explored
graphically and with contingency table analyses. For
descriptive statistics of the study sample, continuous
variables are described as mean and SD if normally
distributed and median and interquartile range (IQR)
if skewed, and categorical variables are described as
proportions (%).
The relationship between sarcopenia and
functional status was assessed using correlation and
logistic regression analyses. Correlations between
continuous KPS and LPA rate of change were
compared using Spearman rho rank correlation
coefficient for ordinal data.44
Testing correlation assumptions revealed a
parabolic relationship between variables, with an
inflection point at 20% increase in LPA per month;
therefore, we reported correlations for patients with
values of less than +20%, which excluded 5 people
(N = 131). Briefly, we assessed linear and monotonic
assumptions of correlation (for Pearson and
Spearman correlation) by exploring scatter plots and
locally weighted scatterplot smoothing-weighted
curves for 10-point KPS scale versus rate of muscle
wasting (% change in LPA/month). Using locally
weighted scatterplot smoothing results in which the
association reverses direction past a certain (extreme)
point and a potential parabolic relationship between
the 2 variables occurs, we explored a squared
transformation of LPA rate. A linear regression model
was run with functional status as the dependent
variable and LPA rate plus a squared (positive value)
transformation of the LPA rate to test whether this
was the case (yes if P value of squared variable was
significant) and to quantify the point of inflection
where the effect reverses. Transformation of the
primary independent variable was decided against
to simplify the primary variable of interest and to
allow ease of interpretation from a clinician’s
perspective. Instead, correlations were assessed in a
sample subset in which the monotonic form in the
relationship between variables held (uniform
direction of effect; that is, no reversal). After
exploring potential explanations for the 5 unlikely
values of increasing LPA at a rate of > 20%/month,
we were unable to determine a definite explanation
that would have otherwise been considered a
conceptually important exclusion criterion.
For power calculations, we assumed normal
distributions of both sarcopenia and functional status
variables, a sample size of 131 patients (after applying
exclusions described in the above paragraph), an
alpha of 0.05, power (1-beta) of 0.80, and a null
correlation of 0. Thus, the smallest correlation
detectible was 0.24 for a two-tailed test (weak
correlation). Given these parameter restrictions, we
may not be able to detect correlations weaker than
0.24.
We evaluated unadjusted and adjusted odds of
severe functional impairment (KPS of 10% to 40%
versus referent [KPS of 50% to 100%]) for 3 working
definitions of muscle wasting: (1) rate of muscle
wasting, (2) pretransplant sarcopenia (yes/no), and
(3) pretransplant LPA (per SD decrease), using
logistic regression and adjusting for age (≥ 55 vs 
< 55 years), sex (women vs men), and race (white vs
non-white ethnicity). Results are presented as odds
ratios (OR) with accompanying 95% confidence
intervals (CI).
Tests of statistical significance were selected as
appropriate based on normality of the dependent
variable. For normally distributed continuous
variables, we used t tests, paired t tests (for baseline
vs pretransplant comparisons), and analysis of
variance. For skewed continuous variables, we used
Wilcoxon rank-sum test for unmatched pairs or
signed-rank test for pairs (baseline vs pretransplant
psoas measures). For categorical variables, we used
chi-square or Fischer exact test for cell sizes < 5.
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P values ≤ .05 were considered significant. All
analyses were conducted using Stata version 13
(StataCorp LP, College Station, TX, USA).
Results
The final study sample included 136 patients who
underwent first-time liver transplant between 2006
and 2015, with 266 patients excluded. In the included
patient sample, the mean age was 55.4 years, 38%
were women, the most common ethnic minority was
Hispanic/Latino (14.7%), and 77.2% of patients were
white, the mean age was 55.6 years and other results
were 39.1%, 11.8%, and 84.4%, respectively, in the
excluded group. Primary causes of liver disease
included hepatitis C/viral hepatitis (47.1%), alcoholic
hepatitis (24.3%), and other liver diseases (28.7%)
versus 34.2%, 38.4%, and 25.9%, respectively, in the
excluded group. Hepatocellular carcinoma was
present in 36.0% of the included versus 16.9% of the
excluded group (P < .001). In the included versus
excluded group, the mean laboratory-calculated
MELD score pretransplant was 22.3 versus 18.7 
(P < .01), with most patients in both groups (68.4%
vs 61.7; P = .20) categorized with Child-Pugh class C
for cirrhosis severity. The median (IQR) wait list time
was 3.2 months (0.8-12.4 mo) versus 3.4 months 
(0.9-10.1 mo) (not significant, P = .96).
Muscle wasting and recipient characteristics
Table 2 shows descriptive statistics of the sample
according to the presence or absence of sarcopenia
on pretransplant CT (in relation to sex-specific
thresholds of “normal” LPA). Patients with sarco -
penia were 5 years older on average, weighed an
average of 20 pounds less, and were twice as likely to
have been previously diagnosed with diabetes
versus those who did not have sarcopenia. Alcoholic
hepatitis was a more common primary cause of liver
disease (29.9% versus 18.8%), and hepatocellular
carcinoma was less likely among patients with
sarcopenia. Patients with sarcopenia had more severe
disease according to pretransplant laboratory MELD
score, laboratory tests, and hospitalization status
(31.3% vs 11.6% in intensive care unit); more than
75% of patients with sarcopenia were classified with
Child-Pugh class C.
Table 3 summarizes changes in psoas muscle
measures by sex, with further details shown in 
Table 4. Most patients showed decline in either
muscle size or density (86.8%), approximately three-
quarters lost TPA, and slightly over one-half declined
in muscle quality (55.2%). We found that 71.3%
declined in LPA from baseline to pretransplant CT
overall (average [IQR] time between scans of 12 mo
[3.6-36.5 mo]). The mean (SD) relative change in LPA
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table 2. Pretransplant Characteristics of Patients Who Underwent Liver
Transplant at UMass Memorial From 2006 to 2015, by Category of Sarcopenia
Versus No Sarcopenia on Pretransplant Computed Tomography (N = 136)
Characteristic Sarcopenia Pretransplant
> 1 SD Below Within Normal 
Normal Limits
(n = 67) (n = 69)
Age ≥ 55 years 70.2 46.4
Women 34.3 33.3
Ethnic minority 25.4 20.3
Primary insurance
Private 43.3 34.8
Public (Medicaid)a 26.9 42.0
Public (Medicare) 29.9 23.2
Body mass index, kg/m2 27.0 (5.5) 29.3 (5.6)
Weight, kg 77.6 (19.3) 86.2 (19.1)
Height, m 1.69 (0.1) 1.71 (0.1)
Diabetes (type 1, type 2, or unspecified) 34.3 14.5
Primary cause of liver disease 
Hepatitis C and similar infections 38.8 55.1
Alcoholic hepatitis 29.9 18.8
Other liver diseases 31.3 26.1
Hepatocellular carcinoma 29.9 42.0
Child-Pugh class
A (mild) 4.5 10.1
B (moderate) 19.4 29.0
C (severe) 76.1 60.9
Wait list time, mo 2.2 (0.6-11.1) 3.6 (1.0-13.0)
Model for End-Stage Liver Disease 
score (laboratory) 24 (16-34) 17 (12-27)
< 15 19.4 43.5
15-29 44.8 34.8
≥ 30 35.8 21.7
Creatinine, mg/dL 2.1 (1.8) 1.5 (1.4)
Total bilirubin, mg/dL 9.4 (10.9) 8.5 (11.5)
International normalized ratio 2.0 (1.4) 2.0 (2.0)
Albumin, g/dL 3.0 (0.7) 3.0 (1.0)
Medical condition
Hospitalized 25.4 27.5
Intensive care unit 31.3 11.6
Life support 17.9 5.8
Psoas muscle density, Hounsfield unit 36.1 (7.6) 43.4 (8.9)
Total psoas area, mm2 1442 (376.9) 2212.3 (491.1)
Results are shown as percent, mean (standard deviation), or median
(interquartile range). Lean psoas areas on pretransplant (≤ 90 days)
abdominal computed tomography that are > 1 standard deviation below
sex-specific averages (cutoff points of 1488.4 mm2 for men and 974.8 mm2 for
women) were reported in a study of 1279 patients admitted for elective
general surgery.37 aIncludes 1 person with insurance type-other.
Relative percent change was calculated as (pretransplant – baseline)/baseline
and shown as median (interquartile range).
aPer month between computed tomography scans, with median
(interquartile range) value of 11.6 months (4.7-41.4 mo) for men and 13.0
months (1.4-33.7 mo) for women (P = .30).
table 3. Changes in Psoas Muscle Measures From Baseline to Pretransplant
Computed Tomography by Sex in Study Group (N = 136)
Relative Change, % Men (n = 90) Women (n = 46)
Total psoas area, mm2 -11.3 (-21.1 to -0.7) -2.9 (-16.7 to 8.9)
Density, Hounsfield unit -1.5 (-20.2 to 12.0) -10.0 (-24.5 to 16.6)
Lean psoas area, mm2 -10.9 (-25.3 to -1.0) -3.4 (-20.3 to 6.4)
Lean psoas area/montha -0.5 (-1.4 to -0.1) -0.1 (-1.6 to 0.8)
was -10.7% (19.9%), and the average rate of relative
change was -0.5% per month (-1.5% to -0.04% per
month).
As shown in Table 3, although TPA and density
changed significantly from baseline to pretransplant
in the overall sample, women only lost a median of
2.9% of baseline TPA compared with 12.6% among
men. In contrast, women significantly declined in
muscle quality (-10.0%; P = .03), whereas men did not
(-1.5%; P = .20). A significant difference persisted
even after accounting for density in LPA. However,
when we normalized relative LPA change for time
(months) between CT scans, differences in muscle
wasting by sex were equalized (P = .07).
Table 5 shows recipient characteristics by tertiles
of rate of LPA loss (% LPA lost per month between
CT scans), and Table 6 shows characteristics by
tertiles of relative LPA loss (%). By tertile of LPA loss
rate, in order of increasing severity, the median (IQR)
change in LPA was 7% (2%-13%), -14% (-26% to -6%),
and -22% (-32% to -12%). Characteristics associated
with more rapid rates of LPA loss included 
higher rate of weight loss per month on the wait 
list, higher laboratory MELD score at registration and
pret ransplant (with worse bilirubin and coagulation
results), and more critical medical condition 
(Table 7). Patients with higher rates of muscle
wasting were less likely to have hepatocellular
carcinoma.
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table 4. Frailty Measures: Sarcopenia and Functional Status by Sex in Study Group (N = 136)
Psoas Measure Men (n = 90) Women (n = 46) P Value (men vs women) All (N = 136)
At baseline CT scan
Time between CT, mo 11.6 (4.7-41.4) 13.0 (1.4-33.7) .30 12.0 (3.6-36.5)
TPA, mm2 2344.3 (551.0) 1518.0 (437.8) < .001 2064.8 (646.5)
Density, HU 42.7 (8.8) 41.4 (10.3) .45 42.3 (9.3)
LPA, mm2 1771.1 (474.4) 1131.1 (349.1) < .001 1554.7 (530.4)
LPA (mm2)/height (m)2 582.7 (157.1) 435.4 (134.1) < .001 532.9 (164.8)
At pretransplant CT scan
Time from pretransplant CT to transplant, days 27 (11-47) 26 (11-60) .89 27 (11-50.5)
TPA, mm2 2028.9 (547.7) 1449.5 (447.7) < .001 1832.9 (583.3)
Density, HU 41.0 (8.3) 37.3 (9.9) .023 39.8 (9.0)
LPA, mm2 1513.2 (451.9) 1048.6 (354.4) < .001 1356.1 (474.5)
LPA (mm2)/height (m)2 499.2 (158.2) 403.8 (133.7) < .001 466.9 (156.6)
Change from baseline to pretransplant CT
Change in TPA, mm2 -266.5 (-496.8 to -13.6) -49.6 (-232.4 to 121.4) .001 -167.6 (-415.3 to 11.6)
%TPA change, mm2 -12.6 (16.4) -3.2 (19.0) .003 -9.5 (17.8)
Change in density, HU -0.6 (-9.9 to 5.4) -4.2 (-11.4 to 4.0) .25 -1.6 (-10.6 to 5.2)
%Density change, HU -1.5 (-20.2 to 12.0) -10.0 (-24.5 to 16.6) .26 -4.5 (-21.1 to 12.3)
Change in LPA, mm2 -175.7 (-445.2 to -17.7) -26.0 (-272.3 to 67.4) .003 -148.2 (-377.4 to 19.1)
%LPA change, mm2 -13.3 (18.6) -5.7 (21.5) .034 -10.7 (19.9)
Change in LPA/height2 -51.6 (-145.7 to -6.1) -10.6 (-101.4 to 28.1) .008 -48.0 (-130.2 to 6.4)
Rate of change
Change in LPA/height2/mo -3.2 (-8.8 to -0.6) -0.5 (-7.0 to 2.8) .031 -2.65 (-8.5 to 0.2)
%LPA change/mo -0.5 (-1.4 to -0.1) -0.1 (-1.6 to 0.8) .07 -0.5 (-1.5 to 0.04)
Abbreviations: CT, computed tomography abdominal scan; HU, Hounsfield unit; LPA, lean psoas area (TPA × density adjustment factor); TPA, total psoas area
(sum of left and right psoas muscles as separate measures for pretransplant and baseline CTs)
Results are shown as mean (standard deviation) or median (interquartile range). Baseline is defined as earliest available abdominal CT scan before pretransplant
CT (with at least 7 days between scans). Percent change was calculated as (pretransplant LPA minus baseline LPA)/baseline LPA (note: height in the
denominator cancels out).
table 5. Characteristics in Relation to Rate of Change of Lean Psoas Area
(Tertiles) in Study Group (N = 136))
Tertiles of Rates of Change (%/mo) in 
Lean Psoas Area Over Baseline†
Highest Moderate) Minimal/No 
(n = 46) (n = 45 Loss (n = 45)
Median (range), -2.75 -0.45 1.13
%/mo (-57.92 to -1.02) (-0.95 to -0.09) (-0.06 to 79.08)
Time between 
CT scans, mo 6.8 (2.7-13.0) 37.6 (16.6-64.8) 8.7 (1.8-35.2)
Characteristic
Age ≥ 55 y 56.5 62.2 55.6
Women 30.4 20.0 51.1
Ethnic minority 17.4 26.7 24.4
Public health 
insurance 56.5 66.7 60.0
Body mass index, 
kg/m2 24.5 (4.9) 29.0 (5.1) 28.1 (6.8)
Weight, kg 81.2 (19.1) 85.4 (16.7) 79.3 (22.5)
Height, m 1.71 (0.1) 1.71 (0.1) 1.67 (0.1)
Diabetes (type 1, 
type 2, or unspecified) 21.7 35.6 15.6
Primary cause of liver 
disease 
Hepatitis C/viral and 
other 45.7 53.3 42.2
Alcoholic hepatitis 23.9 24.4 24.4
Other liver diseases 30.4 22.2 33.3
Hepatocellular 
carcinoma 21.7 44.4 42.2
Time on wait list, mo 1.7 (0.5-6.1) 6.4 (1.5-15.5) 3.0 (0.8-13.9)
Weight loss/month 
on wait list
< 0 to ≤ 5% 28.3 57.8 45.5
> 5% 26.1 8.9 25.0
Laboratory MELD at 
registration 22 (12-29) 14 (10-20) 15 (10-20)
Laboratory MELD 
pretransplant 29 (20-38) 19 (12-24) 16 (12-25)
Creatinine, mg/dL 1.4 (0.9-2.4) 1.0 (0.8-1.6) 1.1 (0.8-2.1)
Total bilirubin, mg/dL 11.1 (3.5-19) 3.0 (1.5-6.1) 3.1 (1.4-6.3)
International normalized 
ratio 2.0 (1.4-2.6) 1.5 (1.2-1.9) 1.4 (1.2-1.8)
Sarcopenia and functional status
Functional impairment (moderate or severe physical
limitations per KPS) was present in 117 patients
(86.0%) at transplant. The mean KPS score was
47.3%, with 31.6% having KPS of 20%. The KPS
distributions did not vary by sex (P = .92).
Figure 2 illustrates the relationship between
continuous functional status and rate of LPA loss. A
moderate correlation was identified (Spearman 
rho = 0.31; P < .001). Table 8 shows the correlations
stratified by recipient characteristics of interest, with
average LPA rates displayed for each category of
functional status.
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Abbreviations: CT, computed tomography; ICU, intensive care unit; MELD,
Model for End-Stage Liver Disease
Results are shown as percent, mean (standard deviation), or median
(interquartile range).
Abbreviations: ICU, intensive care unit; IQR, interquartile range; MELD,
Model for End-Stage Liver Disease
Results are shown as percent, mean (standard deviation), or median
(interquartile range).
table 5. Characteristics in Relation to Rate of Change of Lean Psoas Area
(Tertiles) in Study Group (N = 136))
Tertiles of Rates of Change (%/mo) in 
Lean Psoas Area Over Baseline†
Highest Moderate) Minimal/No 
(n = 46) (n = 45 Loss (n = 45)
Albumin, g/dL 2.9 (2.7-3.3) 2.8 (2.5-3.5) 3.0 (2.4-3.4)
Child-Pugh
B 17.4 24.4 31.1
C 80.4 62.2 62.2
Portal vein thrombosis 17.4 15.6 13.3
Medical condition
Not hospitalized 32.6 57.8 66.7
Hospitalized, not ICU 32.6 26.7 20.0
ICU 34.8 15.6 13.3
Life support 21.7 6.7 6.7
table 6. Characteristics of Liver Transplant Recipients (N = 136) in Relation to
Change in Lean Psoas Area Relative to Baseline (Tertiles) 
Tertiles of Relative Change in Lean Psoas Area
Severe Loss  Moderate) Minimal/No 
of LPA Loss of Loss of LPA 
(n = 46) LPA (n = 45 (n = 45
Median change in  -30.1 -9.1 7.4 
LPA (range) (-64.5 to -19.0) (-1.0 to 46.1) (-1.0 to 46.1)
Median months CT (IQR) 19.7 (8.7-54.9) 9.8 (4.0-31.7) 8.1 (1.8-31.9)
Characteristic
Age ≥ 55 y 65.2 53.3 55.6
Women 26.1 26.7 48.9
Ethnic minority 10.9 33.3 24.4
Public health insurance 54.4 71.1 57.8
Body mass index, kg/m2 27.4 (4.8) 29.1 (5.3) 28.1 (6.7)
Weight, kg 82.6 (18.6) 83.4 (18.2) 79.8 (22.0)
Height, m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1)
Diabetes (type 1,  
type 2, or unspecified) 30.4 26.7 15.6
Primary cause of liver disease 
Hepatitis C/viral or other 50.0 46.7 44.4
Alcoholic hepatitis 21.7 26.7 24.4
Other liver diseases 28.3 26.7 31.1
Hepatocellular c
arcinoma 32.6 31.1 44.4
Time on wait list, mo 2.2 (0.7-11.1) 4.6 (1.5-13.0) 3.0 (0.8-9.1)
Weight loss per month 
on wait list
< 0 to ≤ 5% 41.3 44.4 45.5
> 5% 21.7 13.3 25.0
Laboratory MELD at 
registration 20.5 (11-26) 15 (10-22) 15 (10-20)
Laboratory MELD 
pretransplant 25.5 (16-36) 22 (12-30) 16 (12-24)
Creatinine, mg/dL 1.3 (0.9-2.5) 1.0 (0.8-1.6) 1.1 (0.8-1.8)
Total bilirubin, mg/dL 6.4 (2.8-19) 5.0 (1.7-12.5) 2.9 (1.4-6.1)
International normalized 
ratio 1.7 (1.3-2.2) 1.7 (1.3-2.3) 1.4 (1.1-1.8)
Albumin, g/dL 3.0 (2.5-3.4) 2.8 (2.5-3.5) 3.0 (2.4-3.3)
Child-Pugh
B 19.6 22.2 31.1
C 78.3 66.7 60.0
Portal vein thrombosis 15.2 17.8 13.3
Medical condition
Not hospitalized 41.3 46.7 68.9
Hospitalized, not ICU 26.1 35.6 17.8
ICU 32.6 17.8 13.3
Life support 19.6 8.9 6.7
table 7. Characteristics of Liver Transplant Recipients (N = 136) in Relation
to Functional Status
Functional Impairment/Disability
Severe Moderate None/Normal 
(n = 62) (n = 55) (n = 19)
Median %LPA   -13.1 -9.5 -2.2 
change (range (-33.3 to -1.3) (-20.9 to 4.0) (-8.2 to 0.95)
Median months 
on wait list (IQR) 1.7 (0.39-8.7) 4.3 (1.3-13.0) 3.8 (1.2-13.9)
Median months 16.9
between CT scans (IQR) 10.4 (2.7-43.0) 15.0 (4.8-35.4) (6.1-35.2)
Characteristic
Age ≥ 55 y 56.5 60.0 57.9
Women 33.9 33.2 21.1
Ethnic minority 27.4 18.2 21.1
Public health insurance 66.1 61.8 42.1
Body mass index, 
kg/m2 27.9 (5.6) 29.4 (5.8) 25.6 (4.2)
Weight, kg 80.8 (20.0) 85.9 (20.0) 74.2 (14.4)
Height, m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1)
Diabetes (type 1, type 2, 
or unspecified) 27.4 23.6 15.8
Primary cause of 
liver disease 
Hepatitis C/viral or
other 43.6 49.1 52.6
Alcoholic hepatitis 29.0 25.5 5.3
Other liver diseases 27.4 25.5 42.1
Hepatocellular carcinoma 13.4 40.0 79.0
Weight loss per month 
on wait list
< 0 to ≤ 5% 26.2 16.4 10.5
> 5% 37.7 43.6 63.2
Laboratory MELD at 
registration 21.5 (16-31) 13 (9-17) 10 (7-14)
Laboratory MELD 
pretransplant 29.5 (22-37) 15 (11-24) 12 (9-13)
Creatinine, mg/dL 1.5 (1.0-3.0) 0.9 (0.7-1.5) 0.9 (0.8-1.1)
Total bilirubin, mg/dL 8.6 (3.8-18.8) 2.8 (1.4-6.4) 1.5 (0.9-3.4)
International normalized 
ratio 2.0 (1.7-2.6) 1.3 (1.1-1.7) 1.2 (1.1-1.4)
Albumin, g/dL 3.1 (2.5-3.4) 2.9 (2.4-3.3) 2.8 (2.6-3.5)
Child-Pugh
B 4.8 38.2 47.4
C 95.2 52.7 26.3
Portal vein thrombosis 17.7 14.6 10.5
Medical condition
Not hospitalized 9.7 85.5 94.7
Hospitalized, not ICU 46.8 10.9 5.3
ICU 43.6 3.6 0
Life support 22.6 3.6 0
Abbreviations: ICU, intensive care unit; IQR, interquartile range; MELD,
Model for End-Stage Liver Disease
Results are shown as percent, mean (standard deviation), or median
(interquartile range).
Table 9 shows the results of logistic regression
models for severe functional impairment/disability
by 3 different measures of muscle wasting. Severe
impairment or disability was more common among
patients with higher rates of muscle wasting 
and among those with pretransplant sarcopenia. 
Mean LPA among severely impaired patients 
was 1215.4 mm2 versus 1473.9 mm2 for patients 
who had moderate or normal functional status 
(P = .001). 
Compared with patients with minimal or no
evidence of sarcopenia on CT scan, those who
displayed muscle wasting of ≥ 1% per month had 2.83
times the risk (95% CI, 1.18-6.80) of being severely
impaired, disabled, and/or moribund pretransplant
(adjusted for age, sex, and race). The adjusted odds
ratio observed for those with pretransplant sarcopenia
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Figure 2. Correlationa Between Pretransplant Functional Status and Rate of
Change in Lean Psoas Area From Baseline to Pretransplant in Study Group
(N = 131)
Correlations were assessed using Spearman’s rho for rank-order correlation
between 10-point Karnofsky Performance Status scale and continuous
sarcopenia and restricted to the range of lean psoas area values for which
test assumptions were not violated: below (+) 20% increase in the rate of
relative Lean Psoas Area change/month.
table 8. Rate of Muscle Wasting Versus Functional Status Pretransplant: Stratified Distributions and Correlations of Study Group (N = 136)
table 9. Unadjusted and Adjusted Odds Ratios (95% Confidence Intervals) for Severe Functional
Impairment/Disability by Rate of Muscle Wasting, Pretransplant Sarcopenia, and Decrease in Lean Psoas Area in
Study Group (N = 136)
Sarcopenia, Functional Impairment/Disability Correlation
Rate of Change No. Severe (n = 62) Moderate (n = 55) None (n = 19) (P Value)
All 131 -0.66 (-2.62 to -0.12) -0.29 (-1.43 to 0.56) -0.20 (-0.53 to 0.02) .31 (< .001)
Age, y
< 55 55 -0.83 (-3.71 to -0.12) -0.23 (-1.43 to 1.82) -0.08 (-0.31 to 0.25) .36 (< .01)
≥ 55 76 -0.63 (-2.62 to -0.00) -0.39 (-1.39 to 0.26) -0.33 (-0.65 to -0.09) .25 (.03)
Sex
Women 42 -0.52 (-2.62 to 2.91) -0.06 (-0.95 to 0.56) 0.45 (-0.57 to 6.54) NA
Men 89 -0.72 (-2.5 to -0.33) -0.50 (-1.43 to 0.52) -0.21 (-0.53 to -0.09) .30 (< .01)
Primary liver disease
Hepatitis C/viral 63 -0.72 (-2.44 to -0.13) -0.25 (-1.51 to 0.26) -0.20 (-0.36 to -0.09) .34 (< .01)
Alcohol, Other 68 -0.65 (-5.55 to 1.50) -0.37 (-1.30 to 0.66) -0.18 (-0.63 to 0.13) NA
Hepatocellular carcinoma
None 82 -0.90 (-2.80 to -0.20) -0.25 (-1.95 to 0.26) -0.20 (-0.28 to 6.18) .37 (< .01)
Present 42 -0.21 (-0.56 to -0.05) -0.35 (-1.02 to 0.67) -0.20 (-0.63 to 0.02) NA
Child-Pugh
A or B 43 -0.33 (-0.65 to -0.18) -0.18 (-1.21 to -0.75) -0.20 (-0.53 to 0.02) NA
C 88 -0.72 (-2.69 to -0.03) -0.39 (-1.51 to 0.04) -0.20 (-0.36 to -0.18) .28 (< .01)
Severe Impairment/Disability (patients with KPS 10%-40% versus 50%-100%)
%Impaired Unadjusted Adjusteda
Rate of muscle wastingb
High (≥ 1% loss/mo) 56.5 2.60 (1.11-6.09) 2.83 (1.18-6.80)
Moderate (< 1%-0.1% loss/mo) 46.7 1.75 (0.75-4.11) 1.84 (0.75-4.51)
Minimal/none (< 0.1%/mo) 33.3 Referent Referent
Sarcopenia pretransplantb
> 1 SD below normal 56.7 2.46 (1.23-4.91) 2.67 (1.29-5.52)
Within normal limits 34.8 Referent Referent
Lean psoas area pretransplantc
Per SD unit decrease 1.83 (1.24-2.69) 2.32 (1.44-3.75)
Abbreviations: LPA, lean psoas area; NA, not available
Sarcopenia was determined as relative change in LPA per month = ([LPA within 90 days before transplant minus baseline LPA]/baseline
LPA/months between CT scans) and shown as median (interquartile range). Correlations were not reported for groups that were not sufficiently
powered (< 80%). Correlations were assessed using Spearman rho for rank-order correlation between 10-point Karnofsky Performance Status scale
and continuous sarcopenia and restricted to the range of LPA values for which test assumptions were not violated: below (+) 20% increase in the
rate of relative LPA change/month.
Abbreviations: CT, computed tomography; KPS, Karnofsky Performance Status; SD, standard deviation
aAdjusted for age (≥ 55/< 55 years), sex, and race (white/non-white).
bLean psoas area on pretransplant (≤ 90 days) abdominal CT that is > 1 SD below sex-specific averages (cutoff
points of 1488.4 mm2 for men and 974.8 mm2 for women) reported in a study of 1279 patients admitted for
elective general surgery procedures.37
cDecrease relative to sample distribution at single pretransplant time point.
compared with those without was similar (2.67; 95%
CI, 1.29-5.52). The odds of severe functional
impairment/disability more than doubled for each
SD decrease in lean muscle size on pretransplant CT
(2.32; 95% CI, 1.44-3.75).
Discussion
We present results from the first study to evaluate the
relationship between KPS scale and objective
measures of frailty (sarcopenia) in a liver transplant
population. Prevalence of muscle wasting and
prevalence of functional impairment (KPS ≤ 70%)
pretransplant were almost identical (86.8% vs 86.0%,
respectively). Pretransplant sarcopenia, defined
relative to average in a general surgery population,37
was present in about one-half of the sample.
Our reported prevalence of sarcopenia is
consistent with other studies of liver transplant
patients of 45% and 41%.15,19 We observed differences
between men and women in terms of type of muscle
wasting experienced, with men showing change in
total area and women showing change in quality
(density); these findings are also supported in earlier
reports.12,14,15,19,37 We also report a new finding: after
we accounted for changes in density, relative change
from baseline as a percent, and months over which
the changes occurred, we found that degree of
muscle wasting was no longer statistically different
for men and women (P = .07).
Compared with a study that examined change in
psoas muscle perioperatively (90 days before or after
transplant) in a cohort of general and major vascular
surgery patients, we showed a similar but smaller
proportion of patients who showed declined TPA
(73% vs 83%).45 This minor difference could be
explained by the period of observation: the body
goes through a rollercoaster of physiologic changes
in recovering from major surgery, and trunk muscle
size may substantially decline for bed-bound patients
with postoperative complications from not only
misuse but physiologic stress (eg, infection).
Perioperative change in psoas muscle has been shown
to independently predict mortality among patients
with cirrhosis who are undergoing transjugular
intrahepatic portosystemic shunt procedures.46 For
these reasons, we did not include CT scans performed
within 90 days posttransplant, as the aforementioned
postoperative setting is generally very intensive but
also variable for liver transplant patients.
We found that functional status was associated
with sarcopenia on pretransplant CT and with
change in muscle mass and/or quality (loss of LPA).
Our findings are supported by studies of sarcopenia
in general surgery patients at the University of
Michigan.34,37 In a study of patients ≥ 70 years of age
who were admitted for general surgery procedures,
42% exhibited functional impairment on in-clinic
assessment of physical function (eg, walk test) and
only 22% reported difficulty with activities of daily
living.34 The prevalence of functional impairment in
this population was substantially lower than in our
sample of 136 liver transplant recipients (86.0%).
Despite these differences, the estimates of effect that
the authors found for TPA in relation to difficulties
performing instrumental activities of daily living
were almost identical to our findings (OR of 0.53 per
SD of TPA versus OR of 0.55 per SD increase in LPA
[or TPA] pretransplant) (note that these results are
currently presented in Table 9 as the inverse: OR of
1.83 per SD decrease). We also showed that muscle
wasting of as little as 1% per month is associated with
an almost 3-fold higher risk of severe functional
impairment compared with patients with no sign of
muscle wasting and after adjusting for age, sex, and
race (OR of 2.83; 95% CI, 1.18-6.80).
Implications of results
Around 2005, UNOS/SRTR replaced the previously
collected activities of daily living as the primary
measure of functional status with KPS. However, the
Liver and Intestinal Transplant Committee of OPTN
recently asked that research on using KPS nationally
be pursued as there is concern in the transplant
community about whether it is appropriate to risk-
adjust center outcomes for case mix using a variable
that has not been specifically validated in a liver
transplant population.33 This study found moderate
correlations between provider-assessed KPS and
objective markers of frailty, but more research is
warranted.
Although age was originally conceptualized as
the primary driver of frailty among geriatric
populations and although cachexia, an irreversible
progressive inflammation-based disease, is the driver
of frailty in oncology populations, it is actually
“secondary sarcopenia,” due to chronic disease,
malnutrition, and endocrine abnormalities47 that
drives frailty in end-stage liver disease. This has
important implications for both designing potential
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interventions and for prognostic indications of
sarcopenia in liver transplant patients compared
with other populations.
Because underlying causes of frailty are hypo -
thesized to vary across different groups in which
sarcopenia has been recognized as a strong predictive
variable for outcomes, interventions may also need to
target different deficits or approach the deficits from
different angles. In results of nutrition supple -
mentation in liver disease, meal-induced albumin
synthesis was impaired even in compensated
cirrhotic patients,48 which may be insufficient to
overcome underlying endocrine abnormalities.
Disease courses and prognoses in elderly versus
cirrhosis populations also dramatically differ. In
general populations, frailty is conceptualized as
progressive and mostly irreversible; in contrast, liver
disease populations may have some or potentially all
of these processes reversed after the nonfunctioning
organ is replaced with a new, nondiseased organ. We
call for further research on understanding whether
and which preventive measures (or “prehabilitation”
interventions), some thus far shown to be effective in
other types of major surgeries such as cardiac surgery,
may be needed in a liver transplant population.
Although the literature has shown that sarcopenia
predicts mortality, in a liver transplant population,
functional status predicts mortality, and now we add
that functional status maps onto objective measures
of sarcopenia adequately.
However, it is unclear whether there is a causal
relationship between either variable (functional
status, sarcopenia) and posttransplant outcomes, and
therefore, whether interventions to improve muscle
mass measures would improve outcomes. As has
been shown in the cardiac surgery literature,
intervening to improve muscle mass through physical
training and protein supplementation may not bear
meaningful effects on improving outcomes in
transplant patients. Pathophysiologically, transplant
patients have limited protein metabolism due to
cirrhosis, although, after a new functioning liver is
transplanted, the mechanism improves. In contrast, in
cardiac patients, sarcopenia is likely more related to
peripheral muscle breakdown from underuse, poor
circulation, and so forth, while their ability to
metabolize protein is unaffected. Therefore,
interventions to improve recovery time and
outcomes after surgery by increasing muscle mass
with increased protein intake and physical
rehabilitation may be more limited in liver transplant
patients preoperatively due to their inability to
metabolize protein. In contrast to a cardiac surgery
population where sarcopenia is a marker of overall
frailty, in a liver transplant population, sarcopenia is
a reflection of the combination of liver dysfunction
and overall weakness and frailty, which limits our
ability to infer from interventional studies on cardiac
surgery patients directly to a liver transplant
population.
Strengths and limitations
This work must be considered in the context of its
limitations. Our primary limitation is the relatively
small sample size. This limited the number and types
of analyses that we were sufficiently powered to
conduct. A potential limitation of using single-center
data is generalizability of findings. To address
generalizability of measures, we evaluated sarcopenia
variable definitions using a referent from previously
published averages in a general surgery population
and used percent loss for within-patient changes. A
limitation to the averages that we used as “normal,”
however, is that, although elective general surgery
patients may be healthier than the average liver
transplant patient overall, they are likely sicker than
a general healthy population, as the general surgery
population may include those with trauma and those
who have sarcopenia from other causes (including
cancer and advanced age). This limitation is inherent
to the literature available thus far, and we call for
further research describing general population
prevalence and definition of “normal” for analytic
morphomic methods, which measure psoas at the L4
level specifically and for which no referent values are
published. However, the use of single-center data is
also a strength of this retrospective study, as KPS
assessment protocols and patient population norms
are likely to be more consistent and more
homogenous within a single transplant center than
between centers.
Another major but unavoidable limitation is the
retrospective design of the study, which introduced
potential selection bias. There was potential for
survivor bias by including only transplant recipients
rather than all wait list candidates. In contrast, the
sample may have been biased toward patients who
are sicker, as these patients are more likely to undergo
more frequent abdominal CT scans. We compared
characteristics among patients excluded versus those
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included and found some indication that excluded
patients were less sick. However, the primary outcome
variable, functional status, was not significantly
different between groups. Because sarcopenia and
muscle wasting were associated with cirrhosis severity,
it is possible that our results are exaggerated 
by focusing on a subset of sicker patients. The
retrospective design also meant we were also likely not
able to capture true “baseline” psoas muscle measures.
This study was innovative in its approach by
focusing on clinical translation of our process 
and results: we worked with a radiologist with
fellowship training in abdominal imaging to collect
data in real time. In contrast, most research studies
on sarcopenia rely on expensive and technically
sophisticated Matlab engineering/image processing
software to collect and interpret data. Although
having a single rater for psoas muscle measures
could be a limitation, the high level of technical
expertise and high agreement between measures
(97%) on assessment of intrarater reliability virtually
eliminated this potential threat to validity. We defined
the primary variables, specifically “sarcopenia” and
functional status, using universally available cutoff
points or relative to the patient’s own baseline rather
than only reporting tertiles within our unique
population, which may not necessarily translate to
another center or allow assessment of an individual
patient.
Conclusions
Our results show a moderate correlation between
clinically evident functional impairment/disability,
assessed by providers using the KPS scale, and
sarcopenia, an objective marker of frailty syndrome
that can be measured on abdominal CT scan. Both
the extent and rate of muscle wasting were
significantly associated with pretransplant functional
status on regression modeling, increasing risks of
severe functional impairment/disability by 2- to 3-fold
after adjustment for age, sex, and race/ethnicity.
However, if sarcopenia were a direct objective
representation of clinical functional status, the
correlation coefficients and odds ratios would be
many times greater than we observed. We hypothesize
that sarcopenia and functional status likely measure
different aspects of liver failure and that global health
status in liver transplant patients may be affected by
an array of heterogeneous disease manifestations
that we were unable to dissect due to limited sample
size. More research on the utility of using either or
both measures in prognostication and care of high-
risk liver transplant patients is warranted. Better
understanding and characterization of frailty
syndrome in liver transplant patients holds great
potential for improving clinical care and informing
decision-making for patients on transplant wait lists.
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